Lifespan extension therapy:  A therapeutic mix encompassing Hesperidin and Naringenein, isolated from Citrus Aurantium & among others,  increases life span via up-regulation of its target gene BubR1, 12/October/2017, 7.07 am

Natural product therapy for TIIDM and Metabolic defects: Yangonin, isolated from herb Kava kava/Piper methysticum, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 11/October/2017, 12.57 am
October 10, 2017
Molecular therapy for tuberculosis: Fluoxetine, an antidepressant drug, deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via up regulation of its target gene, 12/October/2017, 10.29  pm
October 12, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports that: Lifespan extension therapy:  A therapeutic mix encompassing Hesperidin and Naringenin, isolated from Citrus Aurantium and among others,  increases life span via up-regulation of its target gene BubR1


What is known? 

Both Hesperidin and Naringenin have been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear. I had published earlier that Hesperidin and Naringenin, individually, may improve insulin sensitivity, promote resistance to bone, immune and motor dysfunction and  extend lifespan through down regulation of p70 S6 Kinase.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, a role for Hesperidin and Naringenin in lifespan extension. A therapeutic mix encompassing Hesperidin and Naringeninby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

Figure 1. A therapeutic mix encompassing Hesperidin and Naringenein may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Hesperidin and Naringenin or their analogues, either alone or in combination with other drugs” may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Hesperidin and Naringenin increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:  A therapeutic mix encompassing Hesperidin and Naringenein, isolated from Citrus Aurantium & among others,  increases life span via up-regulation of its target gene BubR1, 12/October/2017, 7.07 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.